Recently, some PXR polymorphisms (i.e., rs10934498 and rs2472677) were shown to significantly affect exposure to SN-38 and therapeutic outcomes in advanced CRC patients receiving irinotecan (31). The gene discussed is NR1I2; the disease is colorectal carcinoma.